¼¼°èÀÇ °Ç¼±¼º °üÀý¿° Ä¡·áÁ¦ ½ÃÀå
Psoriatic Arthritis Therapeutics
»óǰÄÚµå : 1533753
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 276 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

°Ç¼±¼º °üÀý¿° Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 205¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 106¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â °Ç¼±¼º °üÀý¿° Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 205¾ï ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ 2023-2030³âÀÇ CAGRÀº 9.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñ ½ºÅ×·ÎÀÌµå ¼º Ç׿°ÁõÁ¦(NSAIDS)´ÂÀÌ º¸°í¼­¿¡¼­ ºÐ¼® ÇÑ ºÎ¹® Áß ÇϳªÀ̸ç CAGR 9.3%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§ 66¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñ»ý¹°ÇÐÀû Áúȯ º¯Çü¼º Ç×·ù¸¶Æ¼½º ¾à¹°(DMARDs) ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 9.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 29¾ï ´Þ·¯, Áß±¹Àº CAGR 16.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ °Ç¼±¼º °üÀý¿° Ä¡·áÁ¦ ½ÃÀåÀº 2023³â 29¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 52¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2023-2030³âÀÇ CAGRÀº 16.7%ÀÔ´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 4.6%¿Í 8.5%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 6.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è °Ç¼±¼º °üÀý¿° Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

°Ç¼±¼º °üÀý¿°(PsA)Àº °Ç¼± Áõ»ó°ú °üÀý¿° Áõ»óÀÌ ¾ôÇô ÇÇºÎ¿Í °üÀý ¸ðµÎ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¸¸¼º ¿°Áõ¼º ÁúȯÀÔ´Ï´Ù. ÀÌ ÀÚ°¡¸é¿ª ÁúȯÀº °Ç¼±ÀÇ Æ¯Â¡ÀÎ ºÓÀº ºñ´Ã ¸ð¾çÀÇ ¹ÝÁ¡°ú ÇÔ²² °üÀýÅë, °æÁ÷, º×±â µîÀÇ Áõ»óÀ» µ¿¹ÝÇÏ¿© °æµµ¿¡¼­ ÁßÁõ±îÁö ´Ù¾çÇÑ ÇüÅ·Π³ªÅ¸³³´Ï´Ù. PsAÀÇ °ü¸®´Â °üÀý ¼Õ»óÀ» ¹æÁöÇÏ°í »îÀÇ ÁúÀ» °³¼±Çϱâ À§ÇØ ÇÇºÎ¿Í °üÀý ¸ðµÎÀÇ Áõ»óÀ» ´Ù·ç´Â Á¾ÇÕÀûÀÎ Ä¡·á Á¢±Ù¹ýÀÌ ÇÊ¿äÇÕ´Ï´Ù. PsA Ä¡·áÀÇ Ã¹ ¹øÂ° ¸ñÇ¥´Â ¿°ÁõÀ» ¾ïÁ¦Çϰí, Áõ»óÀ» Á¶ÀýÇϰí, Áúº´ÀÇ ÁøÇàÀ» ¾ïÁ¦ÇÏ´Â °ÍÀÔ´Ï´Ù. Ä¡·á ¿ä¹ýÀº Á¾Á¾ ºñ ½ºÅ×·ÎÀÌµå ¼º Ç׿°ÁõÁ¦(NSAIDs)¿Í ÄÚ¸£Æ¼ÄÚ ½ºÅ×·ÎÀ̵忡 ÀÇÇÑ ÅëÁõ ¹× ¿°Áõ °ü¸®·Î ½ÃÀ۵Ǹç Ãʱâ Ä¡·á°¡ ºÒÃæºÐÇÏ¸é ¸ÞÅ䯮·º¼¼ÀÌÆ®¿Í °°Àº Áúº´ º¯Çü Ç× ·ù¸¶Æ¼½º ¾à¹°(DMARDs)·Î ÀüȯÇÕ´Ï´Ù.

ÃÖ±Ù PsAÀÇ º´Å»ý¸®ÀÇ ÇØ¸íÀÌ Å©°Ô ÁøÀüµÇ¾î PsA¸¦ ÁøÇà½ÃŰ´Â ¸é¿ª°èÀÇ Æ¯Á¤ ¼ººÐÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â »ý¹°ÇÐÀû Á¦Á¦°¡ °³¹ßµÇ¾ú½À´Ï´Ù. ¾Æ´Þ¸®¹«¸¿°ú ¿¡Å¸³Ú¼ÁÆ®·Î ´ëÇ¥µÇ´Â Á¾¾ç ±«»ç ÀÎÀÚ(TNF) ¾ïÁ¦Á¦´Â PsA Ä¡·áÁ¦·Î ÃÖÃÊ·Î ½ÂÀÎµÈ »ý¹°ÇÐÀû Á¦Á¦ Áß ÇϳªÀÌ¸ç °üÀý°ú ÇǺΠÁõ»óÀ» ¿ÏÈ­Çϴµ¥ Å« È¿°ú¸¦ º¸¿´½À´Ï´Ù. ¶ÇÇÑ ÃÖ±Ù¿¡´Â ¼½Å°´©¸¿À̳ª ¿ì½ºÅ×Ű´©¸¿°ú °°Àº IL-17À̳ª IL-23À» Ç¥ÀûÀ¸·Î ÇÏ´Â ÀÎÅÍ·çŲ(IL) ¾ïÁ¦Á¦°¡ µîÀåÇÏ¿© TNF ¾ïÁ¦Á¦¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â ȯÀÚ¿¡°Ô ´Ù¸¥ ÀÛ¿ë±âÀüÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ¾ß´©½º Ű³ª¾ÆÁ¦(JAK) ¾ïÁ¦Á¦ ¹× Æ÷½ºÆ÷µð¿¡½ºÅ×¶óÁ¦ 4(PDE4) ¾ïÁ¦Á¦¿Í °°Àº ÀúºÐÀÚ ¾ïÁ¦Á¦´Â PsAÀÇ Áõ»óÀ» Á¶ÀýÇϴµ¥ È¿°úÀûÀÎ °æ±¸ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ Ä¡·áÁ¦´Â PsAÀÇ Ä¡·á »óȲÀ» º¯È­½Ã۰í ȯÀÚ¿¡ ÀÇÇØ °³º°È­µÈ È¿°úÀûÀÎ ¼±ÅÃÀ» Á¦°øÇÕ´Ï´Ù.

°Ç¼±¼º °üÀý¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ÀÌ ÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÇ·á Àü¹®°¡ÀÇ ÀÎ½Ä ¹× Áø´Ü·ü Çâ»ó µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ¾ß±âµË´Ï´Ù. »ý¸í°øÇаú Á¦¾à ¿¬±¸ÀÇ Áøº¸·Î º¸´Ù È¿°úÀûÀÎ »õ·Î¿î Ä¡·á¹ýÀÌ °³¹ßµÇ°í Ä¡·á ¿É¼ÇÀÌ ³Ð¾îÁö°í ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦¿Í Ç¥Àû Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿´É°ú ºñ±³Àû ¾çÈ£ÇÑ ºÎÀÛ¿ë ÇÁ·ÎÆÄÀÏ¿¡ ÈûÀÔ¾î ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ȯÀÚÀÇ ÇൿÀº º¸´Ù Áøº¸µÇ°í Àü¹®ÀûÀÎ Ä¡·á¸¦ Ãß±¸ÇÏ´Â ¹æÇâÀ¸·Î À̵¿Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÇ·á Á¤º¸¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»ó°ú ¼¼°è °Ç°­ °ü¸® ÀÎÇÁ¶ó °³¼±À» Áö¿øÇÕ´Ï´Ù. ÀÇ·áºñ Áõ°¡¿Í ¸¸¼ºÁúȯ º¸Çè Àû¿ë µî °æÁ¦Àû ¿äÀεµ ½ÃÀå È®´ë¸¦ ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÇöÀç ÁøÇàÁßÀÎ ÀÓ»ó½ÃÇè°ú ½Å±Ô Ä¡·á Ÿ°ÙÀÇ Á¶»ç¿¡ ÀÇÇØ »õ·Ó°Ô °³·®µÈ Ä¡·á¹ýÀÇ µµÀÔÀÌ ±â´ëµÇ¾î KEYWORD ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå°ú Çõ½ÅÀÌ È®½ÇÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀÌ ÇÔ²² PsA·Î °íÅë¹Þ´Â ȯÀÚÀÇ °á°ú¿Í »ýȰÀÇ ÁúÀ» ³ôÀÌ´Â °ÍÀ» ¸ñÇ¥·Î ²÷ÀÓ¾ø´Â Áøº¸°¡ ÀÌ·ç¾îÁö´Â ȯ°æÀÌ ¾ç¼ºµÇ°í ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñÀÇ 36»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Psoriatic Arthritis Therapeutics Market to Reach US$20.5 Billion by 2030

The global market for Psoriatic Arthritis Therapeutics estimated at US$10.6 Billion in the year 2023, is expected to reach US$20.5 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2023-2030. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) segment is estimated at 9.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 16.7% CAGR

The Psoriatic Arthritis Therapeutics market in the U.S. is estimated at US$2.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.2 Billion by the year 2030 trailing a CAGR of 16.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Global Psoriatic Arthritis Therapeutics Market - Key Trends and Drivers Summarized

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects both the skin and joints, intertwining the symptoms of psoriasis with those of arthritis. This autoimmune disorder manifests in various forms, ranging from mild to severe, with symptoms including joint pain, stiffness, and swelling, along with the characteristic red, scaly patches of psoriasis. The management of PsA requires a comprehensive therapeutic approach that addresses both skin and joint symptoms to prevent joint damage and improve quality of life. The primary goal of PsA therapeutics is to reduce inflammation, control symptoms, and inhibit disease progression. Treatment regimens often begin with non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids to manage pain and inflammation, moving on to disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, when initial treatments are insufficient.

In recent years, significant advancements in the understanding of PsA's pathophysiology have led to the development of biologic therapies, which target specific components of the immune system that drive the disease. Tumor necrosis factor (TNF) inhibitors, such as adalimumab and etanercept, were among the first biologics approved for PsA treatment and have shown substantial efficacy in reducing joint and skin symptoms. More recently, interleukin (IL) inhibitors that target IL-17 and IL-23, such as secukinumab and ustekinumab, have been introduced, offering alternative mechanisms of action for patients who do not respond to TNF inhibitors. Additionally, small molecule inhibitors like Janus kinase (JAK) inhibitors and phosphodiesterase 4 (PDE4) inhibitors provide oral therapeutic options that are effective in controlling PsA symptoms. These therapies have transformed the treatment landscape of PsA, providing more personalized and effective options for patients.

The growth in the psoriatic arthritis therapeutics market is driven by several factors, including the increasing prevalence of the disease and a heightened awareness and diagnosis rate among healthcare professionals. Advancements in biotechnology and pharmaceutical research have led to the development of new and more effective treatments, expanding the range of therapeutic options available. The rising demand for biologics and targeted therapies, driven by their efficacy and relatively favorable side effect profiles, significantly contributes to market growth. Moreover, patient behavior is shifting towards seeking more advanced and specialized treatments, supported by greater access to healthcare information and improved healthcare infrastructure globally. Economic factors, such as increased healthcare expenditure and insurance coverage for chronic diseases, further support market expansion. Additionally, ongoing clinical trials and research into novel therapeutic targets promise to introduce new and improved treatments, ensuring sustained growth and innovation in the psoriatic arthritis therapeutics market. These factors collectively foster an environment where continuous advancements are made, aiming to enhance patient outcomes and quality of life for those suffering from PsA.

Select Competitors (Total 36 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â